#AACR24: Hedge Funds Hold These Cancer Companies
We follow the top 33 biopharma-focused hedge funds 💡
Of course, they invest in smid-cap biopharma cancer companies.
See list below. 👇
⇨ held by 5 HFs 🔥
$ACLX: Anito-cel (Ph 2)
$ADAP: Afami-cel (PDUFA)
$BCYC: BT8009 (Ph 1/2)
$CNTA: LB101 (Ph 1/2)
$DAWN: Tovorafenib (PDUFA)
$FATE: FT576 (Ph 1)
$FUSN: FPI-2265 (Ph 2)
$GRCL: GC012F (Ph 1/2)
$INBX: INBRX-109 (Ph 2)
$RAPT: Tivumecirnon (Ph 2)
$RCUS: Domvanalimab (Ph 2/3)
$RLAY: RLY-4008 (Lirafugratinib) (Ph 1/2)
$STRO: Luveltamab Tazevibulin (Ph 2/3)
$SWTX: Nirogacestat (Ph 2)
$ZYME: Zanidatamab (BLA)
See image below for their upcoming catalysts. 📸 👇
Get access to forum post with cancer companies held by 6 or more HFs by becoming an Elite subscriber today!
🚨 40% off AACR sale ends soon...
Data/tools to enhance your bio investing:
⇨ Big Mover stocks to watch
⇨ PDUFA & Catalyst Calendars
⇨ Model Portfolios
• Hedge fund favorites
• Run-Up Plays
Stay on top of your bio investing with our tools...
become an 👉 Elite subscriber today!
This article is not investment or legal advice.
Article history:
First published 4/4/24 EJV & AV
#ACLX #ADAP #BCYC #CNTA #DAWN #FATE #FUSN #GRCL #INBX #RAPT #RCUS #RLAY #STRO #SWTX #ZYME #AACR24